The main—albeit exploratory—finding of our study, the early and sustained improvement of left ventricular filling pressure as indicated by E/eʹ in empagliflozin treated patients might provide important information to better understand the early beneficial effects on HF hospitalization seen in SGLT2 inhibitor outcome trials. Here, SLC5A2 is linked to hydrops fetalis.